Reviewing Leap Therapeutics (LPTX) & Its Competitors

Leap Therapeutics (NASDAQ:LPTX) is one of 451 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its peers? We will compare Leap Therapeutics to related businesses based on the strength of its risk, valuation, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Risk & Volatility

Leap Therapeutics has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Leap Therapeutics’ peers have a beta of 11.34, meaning that their average stock price is 1,034% more volatile than the S&P 500.

Valuation and Earnings

This table compares Leap Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Leap Therapeutics	N/A	-$67.56 million	-1.68
Leap Therapeutics Competitors	$435.56 million	-$68.47 million	-10.62

Leap Therapeutics’ peers have higher revenue, but lower earnings than Leap Therapeutics. Leap Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 4.3% of Leap Therapeutics shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Leap Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Leap Therapeutics	N/A	-247.44%	-146.51%
Leap Therapeutics Competitors	-2,626.20%	-359.54%	-43.35%

Analyst Recommendations

This is a breakdown of recent ratings for Leap Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Leap Therapeutics	1	0	0	0	1.00
Leap Therapeutics Competitors	4842	9971	15977	375	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 118.64%. Given Leap Therapeutics’ peers stronger consensus rating and higher possible upside, analysts plainly believe Leap Therapeutics has less favorable growth aspects than its peers.

Summary

Leap Therapeutics peers beat Leap Therapeutics on 9 of the 13 factors compared.

About Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.